Published online Aug 28, 2025. doi: 10.4329/wjr.v17.i8.107732
Revised: May 4, 2025
Accepted: July 18, 2025
Published online: August 28, 2025
Processing time: 153 Days and 8.8 Hours
Photon-counting detector (PCD) CT represents a transformative advancement in radiological imaging, offering superior spatial resolution, enhanced contrast-to-noise ratio, and reduced radiation dose compared with the conventional energy-integrating detector CT.
To evaluate PCD CT in oncologic imaging, focusing on its role in tumor detection, staging, and treatment response assessment.
We performed a systematic PubMed search from January 1, 2017 to December 31, 2024, using the keywords “photon-counting CT”, “cancer”, and “tumor” to ide
Key findings highlighted the advantages of PCD CT in imaging renal masses, adrenal adenomas, ovarian cancer, breast cancer, prostate cancer, pancreatic tumors, hepatocellular carcinoma, metastases, multiple myeloma, and lung cancer. Additionally, PCD CT has demonstrated improved lesion characterization and enhanced diagnostic accuracy in oncology. Despite its promising capabilities challenges related to data processing, storage, and accessibility remain.
As PCD CT technology evolves, its integration into routine oncologic imaging has the potential to significantly enhance cancer diagnosis and patient management.
Core Tip: Photon-counting detector (PCD) CT represents a paradigm shift in oncologic imaging, offering superior spatial resolution, reduced radiation dose, and enhanced material decomposition compared with conventional CT. This study highlighted the potential of PCD CT in tumor detection, characterization, and therapy response assessment, underscoring its role in advancing precision oncology. By leveraging energy-resolved photon detection, PCD CT enhances lesion conspicuity and quantification, paving the way for improved diagnostic accuracy and personalized treatment strategies.